Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer.
Aged
Antibodies, Monoclonal
/ therapeutic use
Antibodies, Monoclonal, Humanized
/ therapeutic use
Antineoplastic Agents, Immunological
/ therapeutic use
Biomarkers, Tumor
/ metabolism
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Disease-Free Survival
Female
Humans
Kaplan-Meier Estimate
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Nivolumab
/ therapeutic use
Prognosis
Retrospective Studies
Treatment Outcome
Baseline tumor size
immune checkpoint inhibitor
non-small cell lung cancer
overall survival
progression-free survival
tumor burden
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
19
12
2018
revised:
05
01
2019
accepted:
07
01
2019
entrez:
4
2
2019
pubmed:
4
2
2019
medline:
21
3
2019
Statut:
ppublish
Résumé
Immune checkpoint inhibitors (ICI) are a novel medication for non-small cell lung cancer (NSCLC). Recent reports indicated that baseline tumor size (BTS) relates to the efficacy of ICI therapy for melanoma, but no study exists for NSCLC. This study aimed to evaluate the utility of BTS for ICI therapy. Data from 58 patients diagnosed with NSCLC who underwent ICI monotherapy, were retrospectively analyzed. Patients were divided into two groups according to BTS (below 101 mm, above 101 mm). The primary endpoint was progression-free survival (PFS) and the secondary endpoint was overall survival (OS). PFS of patients with a large BTS was significantly shorter than that of those with a small BTS (median; 2.07 [95% confidence interval [CI]=0.99-6.77] months versus 6.39 [95%CI=4.17-11.50] months) (p=0.044). OS of patients with large BTS was also significantly shorter (p<0.01). BTS is a predictive and prognostic negative factor of ICI therapy for NSCLC.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Immune checkpoint inhibitors (ICI) are a novel medication for non-small cell lung cancer (NSCLC). Recent reports indicated that baseline tumor size (BTS) relates to the efficacy of ICI therapy for melanoma, but no study exists for NSCLC. This study aimed to evaluate the utility of BTS for ICI therapy.
PATIENTS AND METHODS
METHODS
Data from 58 patients diagnosed with NSCLC who underwent ICI monotherapy, were retrospectively analyzed. Patients were divided into two groups according to BTS (below 101 mm, above 101 mm). The primary endpoint was progression-free survival (PFS) and the secondary endpoint was overall survival (OS).
RESULTS
RESULTS
PFS of patients with a large BTS was significantly shorter than that of those with a small BTS (median; 2.07 [95% confidence interval [CI]=0.99-6.77] months versus 6.39 [95%CI=4.17-11.50] months) (p=0.044). OS of patients with large BTS was also significantly shorter (p<0.01).
CONCLUSION
CONCLUSIONS
BTS is a predictive and prognostic negative factor of ICI therapy for NSCLC.
Identifiants
pubmed: 30711962
pii: 39/2/815
doi: 10.21873/anticanres.13180
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents, Immunological
0
Biomarkers, Tumor
0
durvalumab
28X28X9OKV
Nivolumab
31YO63LBSN
atezolizumab
52CMI0WC3Y
pembrolizumab
DPT0O3T46P
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
815-825Informations de copyright
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.